STOCK TITAN

[144] GILEAD SCIENCES, INC. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Gilead Sciences (GILD) Form 144 notice records a proposed sale of 3,000 common shares via Morgan Stanley Smith Barney for an aggregate market value of $340,710, with an approximate sale date of 09/15/2025 on NASDAQ. The shares were acquired as performance shares on 01/31/2024. The filing also discloses that Johanna Mercier sold 34,000 shares across three transactions in the past three months (06/16/2025, 07/15/2025, 08/15/2025) generating total gross proceeds of $3,982,524.65. The filer affirms no undisclosed material adverse information and the notice is presented as a live filing.

Gilead Sciences (GILD) Form 144 nota registra una vendita proposta di 3.000 azioni ordinarie tramite Morgan Stanley Smith Barney per un valore di mercato aggregato di 340.710 USD, con una data di vendita approssimativa del 15/09/2025 su NASDAQ. Le azioni sono state acquisite come azioni di performance il 31/01/2024. Il deposito segnala inoltre che Johanna Mercier ha venduto 34.000 azioni in tre operazioni nei ultimi tre mesi (16/06/2025, 15/07/2025, 15/08/2025) generando proventi lordi totali di 3.982.524,65 USD. Il dichiarante afferma che non ci sono informazioni materiale avverse non divulgate e l’avviso è presentato come una pratica di filing live.

Gilead Sciences (GILD) Form 144 registra una venta propuesta de 3,000 acciones ordinarias a través de Morgan Stanley Smith Barney por un valor de mercado agregado de 340,710 USD, con una fecha de venta aproximada el 15/09/2025 en NASDAQ. Las acciones se adquirieron como acciones de rendimiento el 31/01/2024. El registro también revela que Johanna Mercier vendió 34,000 acciones en tres transacciones durante los últimos tres meses (16/06/2025, 15/07/2025, 15/08/2025) generando ingresos brutos totales de 3,982,524.65 USD. El solicitante afirma que no existe información adversa material no divulgada y el aviso se presenta como un registro en vivo.

Gilead Sciences (GILD) Form 144 통지서는 3,000주 보통주를 Morgan Stanley Smith Barney를 통해 매각하려는 제안을 기록하며, 총 시장가치는 340,710 USD이고 2025-09-15 경 NASDAQ에서 매각될 예정입니다. 이 주식은 성과주2024-01-31에 취득되었습니다. 또한 제출서는 지난 3개월 간 Johanna Mercier34,000주를 세 건의 거래로 매각했으며 총 매출액이 3,982,524.65 USD에 이른다고 밝힙니다. 신고자는 비공개의 실질적 악재 정보가 없다고 확인하며 이 통지는 실시간 제출로 제시됩니다.

Gilead Sciences (GILD) Form 144 avis enregistre une vente proposée de 3 000 actions ordinaires via Morgan Stanley Smith Barney pour une valeur marchande totale de 340 710 USD, avec une date de vente approximative le 15/09/2025 sur le NASDAQ. Les actions ont été acquises en tant que actions de performance le 31/01/2024. Le dépôt révèle également que Johanna Mercier a vendu 34 000 actions lors de trois transactions au cours des trois derniers mois (16/06/2025, 15/07/2025, 15/08/2025) générant des produits bruts totaux de 3 982 524,65 USD. Le déposant affirme qu’il n’existe aucune information matérielle défavorable non divulguée et l’avis est présenté comme une soumission en direct.

Gilead Sciences (GILD) Form 144-Mitteilung verzeichnet einen vorgeschlagenen Verkauf von 3.000 Stammaktien über Morgan Stanley Smith Barney zu einem aggregierten Marktwert von 340.710 USD mit einem ungefähren Verkaufsdatum am 15.09.2025 an der NASDAQ. Die Aktien wurden am 31.01.2024 als Leistungsaktien erworben. Die Einreichung offenbart zudem, dass Johanna Mercier in den letzten drei Monaten 34.000 Aktien in drei Transaktionen verkauft hat und Bruttoerträge von 3.982.524,65 USD erzielt wurden. Der Einreicher bestätigt, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen und der Hinweis als Live-Einreichung präsentiert wird.

إشعار النموذج 144 الخاص بـ Gilead Sciences يسجل بيعًا مقترحًا لـ 3,000 سهم عادي عبر Morgan Stanley Smith Barney بقيمة سوقية إجمالية تبلغ 340,710 دولار، مع تاريخ بيع تقريبي في 15/09/2025 في NASDAQ. تم الحصول على الأسهم كـ أسهم أداء في 31/01/2024. كما يكشف التقديم أن جوهانا ميرسير باعت 34,000 سهم في ثلاث معاملات خلال الأشهر الثلاثة الأخيرة (16/06/2025، 15/07/2025، 15/08/2025) محققة عائدات إجمالية قدرها 3,982,524.65 دولار. يؤكد المقدم أنه لا توجد معلومات سلبية مادية غير معلنة، ويُقدَّم الإشعار كتسجيل حي.

Gilead Sciences (GILD) Form 144 通知 记录了通过 Morgan Stanley Smith Barney 拟出售 3,000 股普通股,总体市场价值为 340,710 美元,预估在 NASDAQ 的销售日期为 2025-09-15 左右。这些股票于 2024-01-31绩效股 的形式取得。申报还披露,Johanna Mercier 在过去三个月内(2025-06-162025-07-152025-08-15)通过三笔交易出售了 34,000 股,总毛收入为 3,982,524.65 美元。申报人确认没有未披露的重大不利信息,该通知以实时提交的形式呈现。

Positive
  • Clear compliance with Rule 144 including broker, acquisition date, and past three months of sales
  • Securities originated as performance shares, indicating compensation-related provenance rather than a market purchase
  • Filer affirms no undisclosed material adverse information consistent with Form 144 declarations
Negative
  • Insider sold 34,000 shares in the past three months, totaling $3,982,524.65, which may be viewed negatively by some investors
  • Proposed sale adds supply of shares to market, albeit small relative to outstanding shares (1,240,806,916)

Insights

TL;DR: Routine insider sale of performance shares; not material to Gilead's market cap.

The notice documents a small proposed sale of 3,000 shares worth $340,710 and prior insider sales totaling 34,000 shares for $3.98 million. Relative to the reported outstanding share count of 1.2408 billion, these transactions represent de minimis dilution or supply impact. The shares were granted as performance awards, indicating compensation-related disposition rather than an operational red flag. Overall, this is a routine disclosure under Rule 144 reflecting insider liquidity activity rather than company performance.

TL;DR: Compliance appears proper; disclosure of prior monthly sales is transparent and consistent with Rule 144 practice.

The filer identifies acquisition type, acquisition date, capacity of broker, and past three months of sales by the same person, which aligns with Rule 144 reporting expectations. The representation that the seller has no undisclosed material information is standard. The pattern of periodic sales from the same individual suggests scheduled or staged dispositions commonly seen with vested awards. No governance concerns are evident from the notice alone.

Gilead Sciences (GILD) Form 144 nota registra una vendita proposta di 3.000 azioni ordinarie tramite Morgan Stanley Smith Barney per un valore di mercato aggregato di 340.710 USD, con una data di vendita approssimativa del 15/09/2025 su NASDAQ. Le azioni sono state acquisite come azioni di performance il 31/01/2024. Il deposito segnala inoltre che Johanna Mercier ha venduto 34.000 azioni in tre operazioni nei ultimi tre mesi (16/06/2025, 15/07/2025, 15/08/2025) generando proventi lordi totali di 3.982.524,65 USD. Il dichiarante afferma che non ci sono informazioni materiale avverse non divulgate e l’avviso è presentato come una pratica di filing live.

Gilead Sciences (GILD) Form 144 registra una venta propuesta de 3,000 acciones ordinarias a través de Morgan Stanley Smith Barney por un valor de mercado agregado de 340,710 USD, con una fecha de venta aproximada el 15/09/2025 en NASDAQ. Las acciones se adquirieron como acciones de rendimiento el 31/01/2024. El registro también revela que Johanna Mercier vendió 34,000 acciones en tres transacciones durante los últimos tres meses (16/06/2025, 15/07/2025, 15/08/2025) generando ingresos brutos totales de 3,982,524.65 USD. El solicitante afirma que no existe información adversa material no divulgada y el aviso se presenta como un registro en vivo.

Gilead Sciences (GILD) Form 144 통지서는 3,000주 보통주를 Morgan Stanley Smith Barney를 통해 매각하려는 제안을 기록하며, 총 시장가치는 340,710 USD이고 2025-09-15 경 NASDAQ에서 매각될 예정입니다. 이 주식은 성과주2024-01-31에 취득되었습니다. 또한 제출서는 지난 3개월 간 Johanna Mercier34,000주를 세 건의 거래로 매각했으며 총 매출액이 3,982,524.65 USD에 이른다고 밝힙니다. 신고자는 비공개의 실질적 악재 정보가 없다고 확인하며 이 통지는 실시간 제출로 제시됩니다.

Gilead Sciences (GILD) Form 144 avis enregistre une vente proposée de 3 000 actions ordinaires via Morgan Stanley Smith Barney pour une valeur marchande totale de 340 710 USD, avec une date de vente approximative le 15/09/2025 sur le NASDAQ. Les actions ont été acquises en tant que actions de performance le 31/01/2024. Le dépôt révèle également que Johanna Mercier a vendu 34 000 actions lors de trois transactions au cours des trois derniers mois (16/06/2025, 15/07/2025, 15/08/2025) générant des produits bruts totaux de 3 982 524,65 USD. Le déposant affirme qu’il n’existe aucune information matérielle défavorable non divulguée et l’avis est présenté comme une soumission en direct.

Gilead Sciences (GILD) Form 144-Mitteilung verzeichnet einen vorgeschlagenen Verkauf von 3.000 Stammaktien über Morgan Stanley Smith Barney zu einem aggregierten Marktwert von 340.710 USD mit einem ungefähren Verkaufsdatum am 15.09.2025 an der NASDAQ. Die Aktien wurden am 31.01.2024 als Leistungsaktien erworben. Die Einreichung offenbart zudem, dass Johanna Mercier in den letzten drei Monaten 34.000 Aktien in drei Transaktionen verkauft hat und Bruttoerträge von 3.982.524,65 USD erzielt wurden. Der Einreicher bestätigt, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen und der Hinweis als Live-Einreichung präsentiert wird.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for GILD indicate?

The Form 144 shows a proposed sale of 3,000 common shares of Gilead Sciences valued at $340,710, with an approximate sale date of 09/15/2025 on NASDAQ.

Who is the seller and what recent sales are disclosed?

The filing references sales by Johanna Mercier, who sold 34,000 shares across 06/16/2025, 07/15/2025, and 08/15/2025 for total gross proceeds of $3,982,524.65.

How were the shares being sold originally acquired?

The 3,000 shares subject to the proposed sale were acquired as performance shares on 01/31/2024 from the issuer.

Does the filing state any undisclosed material information?

By signing the notice the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.

Through which broker will the shares be sold?

The proposed sale lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker.
Gilead Sciences Inc

NASDAQ:GILD

GILD Rankings

GILD Latest News

GILD Latest SEC Filings

GILD Stock Data

137.72B
1.24B
0.1%
90.75%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
FOSTER CITY